Press Release

Jan 8, 2020
Cytox appoints Ian Gilham as new Chairman of the Board

8th January 2020: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has appointed Dr Ian Gilham as the new Chairman of the Board. Dr Gilham, who brings significant experience in the commercialisation of diagnostics and life science tools, is also non-executive Chairman of Horizon Discovery plc, genedrive plc, and Biosurfit SA. 

Richard Pither, CEO of Cytox, said: “Ian brings exceptional experience in the industry, from multi-national healthcare corporations to entrepreneurial businesses seeking to break new ground. The Cytox team is looking forward to working with Ian as we progress our lead product  genoSCORETM  through regulatory approval and establish commercialisation relationships with existing and new partners. I would also like to thank Andrew Carr, our outgoing Chairman, who has supported the Company through the development of our technologies and products.”  

Ian Gilham said: ”Cytox is at an exciting phase of its life-cycle, as it moves from product development into commercialisation. I believe the Company’s products will become key technologies in the development of new Alzheimer's treatments, and integral to the future delivery of effective healthcare for Alzheimer's and dementia patients. I’m very excited about the prospects for Cytox and what we are going to achieve in 2020.”

Ian started his career developing novel diagnostics at Celltech, and has held further posts developing diagnostics at Amersham International, Abbott Laboratories, and GlaxoSmithKline before becoming CEO of Axis-Shield managing the sale of the business to Alere in 2011 for £250M.

More recently, Ian was Chairman of molecular diagnostics companies Multiplicom and Elucigene which were acquired by Agilent and Yourgene respectively in the past 2 years.

Ian is an active triathlete, representing Great Britain for more than 10 years in multiple world championships.

 

Company contacts:

Cytox

Richard Pither – CEO

+44 1865 338 018

 

Media contact:

80th Atom

Adam Michael

+44 1223 511338

+44 777 588 1813

Adam@80thAtom.com

 

About Cytox

Without new drug therapies, the economic and healthcare cost burden of dementia - including Alzheimer's disease - is estimated to exceed $1tn per year in the next decade1.  Alzheimer’s – a highly complex disease with risk factors based in genetics, lifestyle, age, and environment – has seen no new approved drug therapy since 2003; and clinical trial failure rates run at 99.6%. Cytox’s products genoSCORETM and genoTORTM use Polygenic Risk Scoring (PRS) to improve clinical trial outcomes through patient stratification and the genetic characterisation of Alzheimer’s disease.

 

References:

1. World Alzheimer’s Report 2015 www.alz.co.uk/research/WorldAlzheimerReport2015.pdf